DaeWong Pharmaceutical Announces Positive Safety Review for Bersiporocin
DaeWong Pharmaceutical Co., Ltd. announced that its idiopathic pulmonary fibrosis (IPF) drug candidate, Bersiporocin (DWN12088), received a recommendation to continue its global Phase 2 clinical trial.
The third Independent Data Monitoring Committee (IDMC) review, held on September 23, confirmed the safety and continuation of the study. Out of 102 planned patients, 94 have been enrolled across Korea and the U.S.
The IDMC conducted an in-depth evaluation of interim safety data from 89 enrolled patients and found no significant safety concerns that would impact the trial's continuation.
The study is progressing as planned, with approximately 92% of the target population enrolled to date.
Author's summary: DaeWong Pharmaceutical's Bersiporocin clinical trial continues.
More News
- Justice unveils blueprint to cut remand population
- Cisco and G42 Deepen US-UAE Technology Partnership to Build Secure, End-to-End AI Infrastructure in the UAE
- The Coming Dementia Crisis—and the Cost of Doing Nothing
- Suspect in Charlie Kirk killing can wear street clothes in court amid ‘extraordinary’ attention | Fulton Sun
- Hero Seekers is an upcoming fantasy RPG set in a world where no one remembers the good guys